Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review.
anticoagulation
brain cancer
direct-acting oral anticoagulants
intracranial hemorrhage
venous thromboembolism
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
21 Oct 2023
21 Oct 2023
Historique:
received:
31
07
2023
revised:
05
10
2023
accepted:
09
10
2023
pubmed:
23
10
2023
medline:
23
10
2023
entrez:
22
10
2023
Statut:
aheadofprint
Résumé
The safety and efficacy of direct-acting oral anticoagulants (DOACs) for therapeutic anticoagulation in the setting of primary or metastatic brain cancer is not known. To conduct a meta-analysis and systematic review of studies that compare the risk of intracranial hemorrhage (ICH) in patients with brain cancer treated with DOACs vs low-molecular-weight heparin (LMWH). A literature search was conducted using PubMed, EMBASE, and Cochrane databases. Summary statistics were obtained by calculating the risk ratio (RR), and heterogeneity across studies was estimated using the I The pooled RR for ICH in patients receiving DOACs vs those receiving LMWH was 0.65 (95% CI, 0.36-1.17; P = .15; I The risk of ICH in patients with brain cancer receiving therapeutic anticoagulation varies by anticoagulation agent and diagnosis of primary or metastatic disease.
Sections du résumé
BACKGROUND
BACKGROUND
The safety and efficacy of direct-acting oral anticoagulants (DOACs) for therapeutic anticoagulation in the setting of primary or metastatic brain cancer is not known.
OBJECTIVES
OBJECTIVE
To conduct a meta-analysis and systematic review of studies that compare the risk of intracranial hemorrhage (ICH) in patients with brain cancer treated with DOACs vs low-molecular-weight heparin (LMWH).
METHODS
METHODS
A literature search was conducted using PubMed, EMBASE, and Cochrane databases. Summary statistics were obtained by calculating the risk ratio (RR), and heterogeneity across studies was estimated using the I
RESULTS
RESULTS
The pooled RR for ICH in patients receiving DOACs vs those receiving LMWH was 0.65 (95% CI, 0.36-1.17; P = .15; I
CONCLUSION
CONCLUSIONS
The risk of ICH in patients with brain cancer receiving therapeutic anticoagulation varies by anticoagulation agent and diagnosis of primary or metastatic disease.
Identifiants
pubmed: 37866517
pii: S1538-7836(23)00779-1
doi: 10.1016/j.jtha.2023.10.011
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interests A.L. reports advisory board honorariums from Pfizer, Bayer, Sanofi, and Novartis. B.J.C. reports funding from Sanofi. J.I.Z. reports prior funding from Incyte and Quercegen and consultancy for Sanofi, CSL Behring, and Calyx. V.I., S.A., T.C., K.T., M.M., and R.P. report no conflicts of interest.